×

Apricus Biosciences to Present at the 13th Annual BIO Investor Forum

SAN DIEGO, Oct. 1, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that Richard Pascoe, Chief Executive Officer, will present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014 at 11:30 a.m. Pacific Time. The meeting will be held at the Palace Hotel in San Francisco, CA. Mr. Pascoe will provide an update on the successful European launch of Vitaros®, the Company's topical treatment for erectile dysfunction. Mr. Pascoe will also provide an overview of the Apricus drug candidate, RayVa, targeted to treat the circulatory condition Raynaud's phenomenon.

A live audio webcast of the presentation can be accessed via the Investors section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 90 days following the presentation.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines to meet the needs of patients. The Company's lead product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and will be commercialized by Apricus' marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The Company's second-generation Vitaros room temperature device is under development and is expected to enhance the product's commercial value. The Company recently initiated a Phase 2a trial for RayVa, the Company's product candidate for the treatment of Raynaud's phenomenon. Femprox®, the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed an approximately 400-subject proof-of-concept study. The Company is currently seeking a strategic partner for Femprox.

For further information on Apricus, visit http://www.apricusbio.com.

CONTACT: Steve Martin Apricus Biosciences Chief Financial Officer ir@apricusbio.com (858) 222-8041 Investors: Angeli Kolhatkar Burns McClellan Senior Vice President akolhatkar@burnsmc.com (212) 213-0006

Source:Apricus Biosciences, Inc.